Key regions: Germany, United States, India, Japan, United Kingdom
The demand for Anti-Rheumatic Drugs in Greece has been on the rise in recent years.
Customer preferences: Patients suffering from rheumatic diseases in Greece have shown a preference for biologic drugs over traditional disease-modifying antirheumatic drugs (DMARDs). This trend is in line with the global market, as biologics have gained popularity due to their targeted approach and higher efficacy rates.
Trends in the market: The market for Anti-Rheumatic Drugs in Greece is expected to continue growing due to the increasing prevalence of rheumatic diseases in the country. The rise in the aging population and sedentary lifestyles are some of the factors contributing to the growth of the market. Additionally, the Greek government's efforts to improve access to healthcare services, including the reimbursement of biologic drugs, have also contributed to the growth of the market.
Local special circumstances: Greece has a high prevalence of rheumatic diseases, with an estimated 10-15% of the population affected. This is higher than the global average, which is around 5%. The high prevalence of rheumatic diseases can be attributed to several factors, including genetic predisposition, environmental factors, and lifestyle choices.
Underlying macroeconomic factors: The Greek economy has been experiencing a period of recovery in recent years, following a long period of economic instability. The recovery of the economy has led to an increase in healthcare spending, which has contributed to the growth of the Anti-Rheumatic Drugs market. Additionally, the Greek government's efforts to improve access to healthcare services, including the reimbursement of biologic drugs, have also contributed to the growth of the market.In conclusion, the Anti-Rheumatic Drugs market in Greece is expected to continue growing due to the increasing prevalence of rheumatic diseases, the government's efforts to improve access to healthcare services, and the country's economic recovery. Patients in Greece have shown a preference for biologic drugs over traditional DMARDs, which is in line with the global market trend.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
